Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?

• Published in: Glycoconjugate journal Vol. 33; no. 4; pp. 645 - 652
• Main Authors: Zhuang, Aowen, Forbes, Josephine M.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2016; Springer Nature B.V
• Subjects: Animals; Biochemistry; Biomedical and Life Sciences; Diabetes; Diabetic Nephropathies - metabolism; Diabetic Nephropathies - pathology; Diabetic neuropathy; Glycation End Products, Advanced - metabolism; Humans; Kidney diseases; Life Sciences; Mini-Review; Pathology; Receptor for Advanced Glycation End Products - metabolism; Diabetic nephropathy; AGEs; Diabetes; OST-48; AGE-R1; Diabetic kidney disease
• ISSN: 0282-0080; 1573-4986
• DOI: 10.1007/s10719-016-9693-z

Diabetic patients are postulated to be in a perpetual state of oxidative stress and inflammation at sites where chronic complications occur. The accumulation of AGEs derived from both endogenous and exogenous sources (such as the diet) have been implicated in the development and progression of diabetic complications, particularly nephropathy. There has been some interest in investigating the potential for reducing the AGE burden in chronic disease, through the action of AGE “clearance” receptors, such as the advanced glycation end-product receptor 1 (AGE-R1). Reducing the burden of AGEs has been linked to attenuation of inflammation, slower progression of diabetic complications (in particular vascular and renal complications) and has been shown to extend lifespan. To date, however, there have been no direct investigations into whether AGE-R1 has any role in modulating normal kidney function, or specifically during the development and progression of diabetes. This mini-review will focus on the recent advances in knowledge around the mechanistic function of AGE-R1 and the implications of this for the pathogenesis of diabetic kidney disease.